US3341417A - Method of and means for diagnosis of ingested drugs with radio-opaque and other indicators - Google Patents

Method of and means for diagnosis of ingested drugs with radio-opaque and other indicators Download PDF

Info

Publication number
US3341417A
US3341417A US472060A US47206065A US3341417A US 3341417 A US3341417 A US 3341417A US 472060 A US472060 A US 472060A US 47206065 A US47206065 A US 47206065A US 3341417 A US3341417 A US 3341417A
Authority
US
United States
Prior art keywords
drug
ingested
type
radio
opaque
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US472060A
Inventor
Edwin S Sinaiko
Original Assignee
Edwin S Sinaiko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edwin S Sinaiko filed Critical Edwin S Sinaiko
Priority to US472060A priority Critical patent/US3341417A/en
Application granted granted Critical
Publication of US3341417A publication Critical patent/US3341417A/en
Anticipated expiration legal-status Critical
Application status is Expired - Lifetime legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • A61K49/0433X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • A61K49/0404X-ray contrast preparations containing barium sulfate

Description

United States Patent 3 341,417 METHOD OF AND MEANS FOR DIAGNOSIS OF INGESTED DRUGS WITH RADIO-OPAQUE AND OTHER INDICATORS Edwin S. Sinaiko, 5555 S. Everett Ave., Chicago, II]. 60627 No Drawing. Filed July 14, 1965, Ser. No. 472,060 Claims. (Cl. 167-845) This application is a continuation-in-part of my copending application Ser. No. 271,887, filed Apr. 10, 1963, now abandoned.

The present invention relates to a novel method and means for the diagnosis of an ingested drug, especially of the barbiturate type, and more particularly to the utilization of a radio-opaque or other indicator or marker to indicate the amount and type of an ingested drug by means of an X-ray of a patients abdomen or urinalysis.

Posioning by barbiturates often involves death after a long period in a coma unless suitable treatment is performed to revive the patient. Many times treatment must be delayed while laboratory tests are performed to determine if drugs have been taken into the system which would result in a coma. Thus, the need for immediate identification, determination of dosage, and determination of the period of time which has elapsed since ingestion is a very important one in the differential diagnosis of coma due to ingested drugs.

The large number of cases of barbiturate poisoning due to heavy sale of these drugs, with or without prescriptions, has focused attention upon the necessity of identifying the barbiturates and their metabolites. According to known texts on toxicology the methods of identification of the barbiturates are many and slow, and none are completely satisfactory. To successfully identify such compounds, the group must be isolated from the viscera. The common fluids used for analysis to determine if drugs are involved are stomach washes, blood and urine, and the quickest extraction procedures for all these fluids is a direct extraction using ether of chloroform as the organic solvent.

However, each of these fluids have disadvantages in their analysis. For example, considerable quantities of the barbiturates are lost in the formation of water soluble salts. Such loss also depends on the pH of the solution in the stomach. In blood tests, chromagenes interfere with the identification of assay and, therefore, the chromagenes must be extracted with chloroform. In the urine, the metabolites of barbiturates are also present and identification is difficult because the extract crystallizes and these crystals are not specific.

Polymorphic forms of many barbiturates exist, and X-ray defraction techniques are utilized for identification, and also different solvent techniques and micro melting points are useful. A more recent technique is the purification using chromatography and counter-current techniques followed by identification. Other routine methods of analysis are X-ray diffraction, infra-red spectrophotometry and assay by means of ultra-violet spectrophotometry. However, all of these analysis techniques require considerable time for proper determination and, in the meantime, valuable time is lost before proper treatment may be prescribed.

An important object of the present invention is the provision of a novel indicator to aid in the differential diagnosis of coma. More specifically, this invention relates to a novel method and means to definitely diagnose the 3,341,417 Patented Sept. 12, 1967 cause of coma as due to ingested drugs through a quick and simple test which is easily performed on the patient in coma, without the attendant disadvantages found in prior diagnostic procedures.

Another important object of the present invention is the provision of a method for determining the type of an ingested drug, the amount of the ingested drug and the approximate time elapsed since ingestion. This method involves the addition to the dosage units of the drug marketed for oral ingestion of a non-toxic, relatively insoluble radio-opaque substance which will be visible upon the taking of an X-ray of the patients abdomen. By observing the shape or configuration of the radioopaque substance, the number or amount of the substance and the position or location of the substance in the gastrointestinal tract, one can readily diagnose these three variables cited above.

The present invention further comprehends the provision of a relatively insoluble radio-opaque marker or indicator which may be incorporated in a dosage unit of the drug marketed for oral ingestion with the indicator of a distinct shape or design which may be quickly determined and disclosed by X-ray. Thus, various drugs may be identified by a distinctively shaped marker in the dosage unit of that drug. Further, knowing the marker utilized in a certain dosage unit such as tablet, pill or capsule, one may diagnose the quantity of the drug taken by the number of markers in the patients abdomen or intestinal tract.

The present invention also comprehends the provision of a relatively insoluble radio-opaque marker or indicator incorporated in a gelatin capsule containing the drug to be ingested. The radio-opaque marker is barium sulfate which is incorporated in the gelatin capsule by mixing a liquid suspension of barium sulfate and a gelatin solution and forming the gelatin capsule with the barium sulfate incorporated therein in a conventional manner.

The present invention also comprehends the provision of an indicator incorporated into a dosage unit which will appear in the urine of the patient, such as methylene blue and certain other azo dyes of different distinctive colors. Thus, the urine of a patient in coma would exhibit the distinctive dye substance.

Further objects and advantages of my invention should be apparent to those skilledin the art from the following description.

This invention relates to differential diagnosis of coma and more particularly to whether coma was induced due to ingested drugs. A doctor is frequently called in to see a patient in coma. The differential diagnosis of coma is o ten difiicult because of the various numerous conditions which might cause it, and causes must be ruled out one by one before definitive treatment can be instituted.

Since barbiturate poisoning is not an uncommon 0ccurrence, an immediate method of determining its ingestion would considerably shorten the time required for diagnosis. The present invention concerns the incorporation into each dosage unit of the drug a non-toxic, relatively insoluble indicator such as a radio-opaque marker providing a distinctive shape or configuration which would be ingested simultaneously with the drug. A patient in coma could then have an ordinary X-ray (fiat plate) of the abdomen and the marker would show up on the X-ray plate to indicate the type of drug, quantity and dosage that had been ingested, and treatment could be immediately instituted.

Barbiturates are normally divided into three chemical groups having varying times of duration of effectiveness:

The R-l,5,5 group are long duration compounds, the R-5,5 group are of intermediate duration and the thiobarbiturates are of relatively short duration. Most of these compounds are in the sodium salt form at the number 1 position on the ring as follows:

Pentothal sodium is a thiobarbiturate with R-ethyl and R'CHaCH2CHzCH.

Another well known barbiturate is phenobarbital which is in the R-5,5' group with R-ethyl and R'-phenyl. Although there are three groupings for the barbiturates, their treatment is substantially identical. Treatment involves the persistent administration of central nervous system stimulants (stimulant analeptics), such as picrotoxin, pentylene-tetrazol, nikethamide or bemegride, various supportive procedures, and artificial respiration or oxygen if necessary.

Since treatment for barbiturate poisoning is generally the same for all types of barbiturates, the problems are resolved to the dosage and the time when the drug was ingested. Although the effect of barbiturates in toxic doses on the mobility of the gastrointestinal tract is to slow it and produce stasis, knowing where the drug lies spatially in the tract may be an important advantage in treating the patient. The location of the radio-opaque indicator in the X-ray plate would give a clue as to where in the intestine the drugs (if not completely absorbed) were, and some indication in the time needed to reach that level; therefore, the approximate time when the drug was taken.

Now referring specifically to the radio-opaque indicators which are contemplated for use in the dosage units marketed for oral ingestion. One such indicator is a treated insoluble cord or thread which is radio-opaque, which may be incorporated in a standard size gelatin capsule. Dosages of drugs such as barbiturates are generally standardized quantities. Thus, adding a small section of a cord of a radio-opaque material to the contents of each unit having a known dosage will indicate that drug and quantity if shown on an X-ray plate. If there are several different dosage quantities for the drug, the radio-opaque cord marker will be distinctive for each dosage level. For example, one dosage quantity would have a straight cord in the unit or capsule, a different dosage would have a cord knotted at short intervals, a third dosage could have a cord which has a coiled configuration and a fourth dosage could be a complete circle of the radio-opaque material. Such a cord is formed of polyvinyl chloride and barium sulfate; the barium sulfate being a commonly used radio-opaque material.

Another type of marker which may be incorporated in a dosage unit of the drug marketed for oral ingestion would be a small ball of stainless steel or like material which would be unaifected by the stomach acids or other fluids in the body and which would be nontoxic so as not to be injurious to the health of the person. To differentiate between different dosage levels, the stainless steel member may take a number of shapes which would be easily recognizable upon an X-ray plate, such as a sphere or ball, a square or polygonal shape, an ellipsoid, a star, etc.

A third type of radio-opaque marker or indicator is the utilization of barium sulfate incorporated in the capsule body holding the drug to be ingested. A liquid suspension of barium sulfate and gelatin in water is mixed together and gelatin capsules are formed with the barium sulfate incorporated in the gelatin capsule wall; the capsules being formed in a conventional manner. The capsules will show up on an X-ray plate in the distinctive shape of the capsule due to the barium sulfate, and the barium sulfate will still be clearly seen on an X-ray even where the capsule has completely dissolved.

The distinctive marker could also be formed of a radio-opaque plastic of a distinctive shape or configuration, either two or three dimensional, which may be incorporated in the drug in the pill or capsule, or the plastic marker may be incorporated in the wall of the gelatin capsule. Also, rather than the use of barium sulfate, a radio-opaque ink may be utilized to provide a distinctive marking on the wall of the capsule.

A fourth type of radio-opaque marker involves the use of a radio-opaque plastic which is extruded into a hollow tube having a distinctive cross section. Such a radio-opaque plastic would be a polyvinyl chloride plastic impregnated with barium sulfate. The hollow interior of the extruded tubing may have a variety of distinctive shapes or peripheries only limited by the complexity of the extrusion die. The barbiturate or other medicine is inserted into the hollow tubing as a powder or in a suspension and solidified to provide a solid core in the tube. Then the tubing is sliced transversely to provide the individual dosage unit and coated with an ultimate candy coating that dissolves in the stomach. The plastic tubing will not dissolve and thus will show up on an X-ray plate. Such a plastic would not be toxic to the individual.

Although the description of this invention has dealt primary with barbiturate poisoning which is presently the most common source of poisoning producing coma, this concept of radio-opaque markers may be advantageously applied to other drugs which may produce coma or whenever or wherever it would be deemed expedient for medical intelligence to determine objectively time of ingestion and dosage. The varying configurations of the markers could differentiate between drugs as well as differentiating between dosage levels.

Another type of indicator which may be incorporated in a solid dosage unit of a drug marketed for oral ingestion would be the use of certain azo dyes of different colors, such as methylene blue, which would appear in the urine of the patient. Although the patient is in a comatose condition, the patient would be catheterized and the urine removed would exhibit the dye substance found in the drug. Various types of drugs capable of causing coma would contain various easily identifiable azo dye colors, and this indicator would not be limited to solid dosage units but could also be incorporated in liquids, solutions or elixirs.

By the use of the markers in the drugs to be ingested or in the body of the capsule or pill, a doctor can tell by the number, configuration and location of a marker on an X-ray plate the type of drug, the dosage and number of dosage units ingested, and the approximate time of ingestion. These factors will determine the treatment to be followed and the degree of intensity of treatment.

In the foregoing description, the drugs are generally identified as dosage units marketed for oral ingestion and it is intended such shall include capsules, pills or tablets incorporating the drug therein in a standard dosage used for treatment purposes.

Having thus disclosed the invention, I claim:

1. A method of determining durg poisoning by in vivo roentgenographic identification of ingested peroral dosage units of drugs in a comatose subject, which comprises roentgenographing the gastro-intestinal tract of a comatose subject who has previously ingested peroral dosage units, each containing therein a specific amount and type of drug and a distinctively shaped radiopaque marker identifying that specific amount and type of drug, in order to thereby identify such markers present.

2 A method of determining drug poisoning as set forth in claim 1, in which the number of radiopaque markers indicated on the roentgenograph indicates the number of dosage units ingested and their position in the gastro-intestinal tract indicates the approximate time of ingestion.

3. A method of determining drug poisoning by in vivo roentgenographic identification of ingested peroral dosage units of drugs in a comatose subject, which comprises roentgenographing the gastro-intestinal tract of a comatose subject who has previously ingested peroral capsules, each containing therein a specific amount and type of drug and a specific type of distinctively configured radiopaque material incorporated in the capsule wall identifying that specific amount and type of drug, in order to thereby identify such markers present.

4. A method of determining drug poisoning by in vivo roentgenographic identification of ingested peroral dosage units of drugs in a comatos subject, which comprises roentgenographing the gastro-intestinal tract of a comatose subject who has previously ingested peroral capsules, each containing therein a specific amount and type of drug and a specific type of distinctive confiugred shaped radiopaque marker identifying that specific amount and type of drug, in order to thereby identify such markers present.

5. A method of determining drug poisoning as set forth in claim 4, in which the radiopaque marker is distinctively shaped to indicate the dosage level of the drug.

6. A method of determining barbiturate poisoning by in vivo roentgenographic identification of ingested peroral dosage units of barbiturate drugs in a comatose subject, which comprises roentgenographing the gastrointestinal tract of a comatose subject who has previously ingested peroral dosage units, each containing therein a specific amount and type of barbiturate drug and a specific type of distinctively configured shaped radiopaque marker identifying that specific amount and type of barbiturate drug, in order to thereby identify such markers present.

7. A method of determining barbiturate poisoning by in vivo roentgenographic identification of ingested peroral dosage units of barbiturate drugs in a comatose subject, which comprises roentgenographing the gastrointestinal tract of a comatose subject who has previously ingested peroral dosage units, each containing therein a specific amount and type of barbiturate drug and a specific type of distinctively configured shaped radiopaque marker embedded therein identifying that specific amount and type of barbiturate drug, in order to thereby identify such markers present.

8. A method of determining barbiturate poisoning as set forth in claim 7, in which varying dosages of the barbiturate drug are indicated by different configurations of said marker, and the number and position of the markers indicate the number of dosage units ingested and the approximate time of ingestion.

9. A method of determining drug poisoning by identification of azo dye in the urine of a comatose subject, which comprises catheterizing urine from a comatoes subject who has previously ingested peroral dosage units, each containing therein a specific amount and type of drug and a specific type of azo dye distinctively identifying that specific amount and type of drug, in order to thereby identify the type of azo dye present.

10. A method of determining barbiturate poisoning by identification of azo dye in the urine of a comatose subject, which comprises catheterizing urine from a comatose subject who has previously ingested peroral dosage units, each containing therein a specific amount and type of barbiturate drug and a specific type of azo dye distinctively identifying that specific amount and type of barbiturate drug, in order to thereby identfy the type of azo dye present.

References Cited UNITED STATES PATENTS 2,072,302 3/1937 Herrmann et al. 128335.5 2,330,718 9/1943 Kallmann 283-8 3,146,169 8/1964 Stephenson et al 16782 FOREIGN PATENTS 866,924 5/1961 Great Britain. 936,386 9/1963 Great Britain. 972,128 10/ 1964 Great Britain.

OTHER REFERENCES Collier Lancet, pages 473 to 475, Mar. 3, 1962.

Dewey et al.: Nature 181: 1367 to 1371, May 17, 1958.

Feinblatt et al.: New Eng. J. Med. 254, 290 to 943, May 17, 1956.

Hammerness et al.: I. A. Ph. 358, June 1954.

Hastings: Pharm. I. 184 1960.

Skerman et al.:

November 1959.

Thompson et al.: J. A. Ph. (1945). 19Zlhitney: Brit. Med. J. (5165), pages 50 to 51, Jan. 2,

LEWIS GOTTS, Primary Examiner. S. K. ROSE, Assistant Examiner.

A. (Sci. Ed.) 43, 357 to (5020), 45 to 47, Jan. 16,

Am. J. Vet. Res. 20, 977 to 984,

A. (Sci. Ed.) 34, to 138

Claims (1)

1. A METHOD OF DETERMINING DURG POISONING BY IN VIVO ROENTGENOGRAPHIC IDENTIFICATION OF INGESTED PERORAL DOSAGE UNITS OF DRUGS IN A COMATOSE SUBJECT, WHICH OMCPRISES ROENTGENOGRAPHING THE GASTRO-INTESTINAL TRACT OF A COMATOSE SUBJECT WHO HAS PREVIOUSLY INGESTED PERORAL DOSAGE UNITS, EACH CONTAINING THEREIN A SPECIFIC AMOUNT AND TYPE OF DRUG AND A DISTINCTIVELY SHAPED RADIOPAQUE MARKER IDENTIFYING THAT SPECIFIC AMOUNT AND TYPE OF DRUG, IN ORDER TO THEREBY IDENTIFY SUCH MARKERS PRESENT.
US472060A 1965-07-14 1965-07-14 Method of and means for diagnosis of ingested drugs with radio-opaque and other indicators Expired - Lifetime US3341417A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US472060A US3341417A (en) 1965-07-14 1965-07-14 Method of and means for diagnosis of ingested drugs with radio-opaque and other indicators

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US472060A US3341417A (en) 1965-07-14 1965-07-14 Method of and means for diagnosis of ingested drugs with radio-opaque and other indicators

Publications (1)

Publication Number Publication Date
US3341417A true US3341417A (en) 1967-09-12

Family

ID=23874040

Family Applications (1)

Application Number Title Priority Date Filing Date
US472060A Expired - Lifetime US3341417A (en) 1965-07-14 1965-07-14 Method of and means for diagnosis of ingested drugs with radio-opaque and other indicators

Country Status (1)

Country Link
US (1) US3341417A (en)

Cited By (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3818229A (en) * 1970-12-21 1974-06-18 Univ Illinois Radiopaque agents comprising brominated perfluorocarbons
US4193985A (en) * 1977-03-30 1980-03-18 A/S Alfred Benzon Multiple-units drug dose
US4339463A (en) * 1979-08-24 1982-07-13 Shionogi & Co., Ltd. Enterosoluble hard-capsulated medicaments
US4863470A (en) * 1985-03-19 1989-09-05 Medical Engineering Corporation Identification marker for a breast prosthesis
US4900557A (en) * 1984-08-30 1990-02-13 Troponwerke Gmbh & Co. Kg Pellet formulation
US5368027A (en) * 1992-04-23 1994-11-29 Avl Medical Instruments Ag Sensor arrangement for direct or indirect optical determination of physical or chemical properties
US5460798A (en) * 1992-06-22 1995-10-24 Barnett; Patrick A. System for determining the quantity and identity of material ingested by user
US6347241B2 (en) * 1999-02-02 2002-02-12 Senorx, Inc. Ultrasonic and x-ray detectable biopsy site marker and apparatus for applying it
US6497706B1 (en) 1998-03-03 2002-12-24 Senorx, Inc. Biopsy device and method of use
US6638234B2 (en) 1998-03-03 2003-10-28 Senorx, Inc. Sentinel node location and biopsy
US20030233101A1 (en) * 2002-06-17 2003-12-18 Senorx, Inc. Plugged tip delivery tube for marker placement
US6679851B2 (en) 1998-09-01 2004-01-20 Senorx, Inc. Tissue accessing and anchoring device and method
US6725083B1 (en) 1999-02-02 2004-04-20 Senorx, Inc. Tissue site markers for in VIVO imaging
US6758848B2 (en) 1998-03-03 2004-07-06 Senorx, Inc. Apparatus and method for accessing a body site
US20040236211A1 (en) * 2003-05-23 2004-11-25 Senorx, Inc. Marker or filler forming fluid
US20040236212A1 (en) * 2003-05-23 2004-11-25 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US6875182B2 (en) 1998-03-03 2005-04-05 Senorx, Inc. Electrosurgical specimen-collection system
US20050119562A1 (en) * 2003-05-23 2005-06-02 Senorx, Inc. Fibrous marker formed of synthetic polymer strands
US20050143656A1 (en) * 1999-02-02 2005-06-30 Senorx, Inc. Cavity-filling biopsy site markers
US20060084865A1 (en) * 1999-02-02 2006-04-20 Burbank Fred H Imageable biopsy site marker
US20060241411A1 (en) * 2005-04-20 2006-10-26 Inrad, Inc. Marking device with retracable cannula
US20080039819A1 (en) * 2006-08-04 2008-02-14 Senorx, Inc. Marker formed of starch or other suitable polysaccharide
US20080108949A1 (en) * 2006-11-08 2008-05-08 C. R. Bard, Inc. Resource information key for an insertable medical device
US7377902B2 (en) 1998-04-08 2008-05-27 Senorx, Inc. Biopsy anchor device with cutter
US20080140025A1 (en) * 2005-03-04 2008-06-12 C. R. Bard, Inc. Access port identification systems and methods
US20090156928A1 (en) * 2007-11-07 2009-06-18 C. R. Bard, Inc. Radiopaque and septum-based indicators for a multi-lumen implantable port
US20090171198A1 (en) * 2006-08-04 2009-07-02 Jones Michael L Powdered marker
US7572236B2 (en) 2005-08-05 2009-08-11 Senorx, Inc. Biopsy device with fluid delivery to tissue specimens
US20100010341A1 (en) * 2006-12-18 2010-01-14 Talpade Dnyanesh A Biopsy Marker with In Situ-Generated Imaging Properties
US20100030072A1 (en) * 2006-12-12 2010-02-04 Casanova R Michael Multiple Imaging Mode Tissue Marker
US20100082102A1 (en) * 2008-09-23 2010-04-01 Senorx, Inc. Porous bioabsorbable implant
US20100268165A1 (en) * 2005-03-04 2010-10-21 C. R. Bard, Inc. Systems and methods for radiographically identifying an access port
US20100298698A1 (en) * 2000-11-20 2010-11-25 Senorx, Inc. Tissue site markers for in vivo imaging
US20100298696A1 (en) * 2003-11-17 2010-11-25 Bard Peripheral Vascular, Inc. Self-contained, self-piercing, side-expelling marking apparatus
US20100331668A1 (en) * 2008-01-31 2010-12-30 Ranpura Himanshu M Biopsy Tissue Marker
US20110009828A1 (en) * 2009-07-07 2011-01-13 C.R.Bard, Inc. Extensible internal bolster for a medical device
US20110028836A1 (en) * 2008-12-30 2011-02-03 Himanshu Ranpura Marker delivery device for tissue marker placement
US20110082547A1 (en) * 1997-10-10 2011-04-07 Senorx, Inc. Tissue marking implant
US20110118677A1 (en) * 2009-11-17 2011-05-19 C. R. Bard, Inc. Overmolded access port including anchoring and identification features
US7947022B2 (en) 2005-03-04 2011-05-24 C. R. Bard, Inc. Access port identification systems and methods
US20110166448A1 (en) * 1999-02-02 2011-07-07 Jones Michael L Marker delivery device with releasable plug
US20110184449A1 (en) * 2006-08-04 2011-07-28 Senorx, Inc. Marker delivery device with obturator
US20110184280A1 (en) * 1999-02-02 2011-07-28 Jones Michael L Intracorporeal marker and marker delivery device
US8021324B2 (en) 2007-07-19 2011-09-20 Medical Components, Inc. Venous access port assembly with X-ray discernable indicia
US8025639B2 (en) 2005-04-27 2011-09-27 C. R. Bard, Inc. Methods of power injecting a fluid through an access port
US8177762B2 (en) 1998-12-07 2012-05-15 C. R. Bard, Inc. Septum including at least one identifiable feature, access ports including same, and related methods
US8202259B2 (en) 2005-03-04 2012-06-19 C. R. Bard, Inc. Systems and methods for identifying an access port
US8257325B2 (en) 2007-06-20 2012-09-04 Medical Components, Inc. Venous access port with molded and/or radiopaque indicia
US8317725B2 (en) 2005-08-05 2012-11-27 Senorx, Inc. Biopsy device with fluid delivery to tissue specimens
US8343071B2 (en) 2004-12-16 2013-01-01 Senorx, Inc. Biopsy device with aperture orientation and improved tip
USD676955S1 (en) 2010-12-30 2013-02-26 C. R. Bard, Inc. Implantable access port
US8437834B2 (en) 2006-10-23 2013-05-07 C. R. Bard, Inc. Breast marker
USD682416S1 (en) 2010-12-30 2013-05-14 C. R. Bard, Inc. Implantable access port
US8486028B2 (en) 2005-10-07 2013-07-16 Bard Peripheral Vascular, Inc. Tissue marking apparatus having drug-eluting tissue marker
US8579931B2 (en) 1999-06-17 2013-11-12 Bard Peripheral Vascular, Inc. Apparatus for the percutaneous marking of a lesion
US8641676B2 (en) 2005-04-27 2014-02-04 C. R. Bard, Inc. Infusion apparatuses and methods of use
US8641640B2 (en) 2005-05-23 2014-02-04 Senorx, Inc. Tissue cutting member for a biopsy device
US8668737B2 (en) 1997-10-10 2014-03-11 Senorx, Inc. Tissue marking implant
US8932271B2 (en) 2008-11-13 2015-01-13 C. R. Bard, Inc. Implantable medical devices including septum-based indicators
US9149341B2 (en) 1999-02-02 2015-10-06 Senorx, Inc Deployment of polysaccharide markers for treating a site within a patient
US9265912B2 (en) 2006-11-08 2016-02-23 C. R. Bard, Inc. Indicia informative of characteristics of insertable medical devices
US9408592B2 (en) 2003-12-23 2016-08-09 Senorx, Inc. Biopsy device with aperture orientation and improved tip
US9474888B2 (en) 2005-03-04 2016-10-25 C. R. Bard, Inc. Implantable access port including a sandwiched radiopaque insert
US9610432B2 (en) 2007-07-19 2017-04-04 Innovative Medical Devices, Llc Venous access port assembly with X-ray discernable indicia
US9927448B1 (en) * 2017-03-22 2018-03-27 David R. Hall Method of measuring food dyes in bodily waste to identify and quantify drug consumption
US9950150B2 (en) 2009-10-16 2018-04-24 Smiths Medical Asd, Inc. Portal with septum embedded indicia
US10145856B2 (en) * 2017-03-22 2018-12-04 Hall Labs, Llc Drug tracking system including food dyes detectable in bodily waste

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2072302A (en) * 1931-03-10 1937-03-02 Chemische Forschungs Gmbh Polymerized vinyl alcohol articles and processes of making same
US2330718A (en) * 1942-01-05 1943-09-28 Heinz E Kallmann Bank note
GB866924A (en) * 1956-11-05 1961-05-03 Commw Scient Ind Res Org Improved means for supplying small amounts of nutritional or therapeutic substances to ruminants
GB936386A (en) * 1959-01-16 1963-09-11 Wellcome Found Pellets for supplying biologically active substances to ruminants
US3146169A (en) * 1960-01-21 1964-08-25 Burroughs Wellcome Co Pharmaceutical formulations and their manufacture

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2072302A (en) * 1931-03-10 1937-03-02 Chemische Forschungs Gmbh Polymerized vinyl alcohol articles and processes of making same
US2330718A (en) * 1942-01-05 1943-09-28 Heinz E Kallmann Bank note
GB866924A (en) * 1956-11-05 1961-05-03 Commw Scient Ind Res Org Improved means for supplying small amounts of nutritional or therapeutic substances to ruminants
GB936386A (en) * 1959-01-16 1963-09-11 Wellcome Found Pellets for supplying biologically active substances to ruminants
US3146169A (en) * 1960-01-21 1964-08-25 Burroughs Wellcome Co Pharmaceutical formulations and their manufacture
GB972128A (en) * 1960-01-21 1964-10-07 Wellcome Found Pellets for supplying biologically active substances to ruminants and the manufacture of such pellets

Cited By (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3818229A (en) * 1970-12-21 1974-06-18 Univ Illinois Radiopaque agents comprising brominated perfluorocarbons
US4193985A (en) * 1977-03-30 1980-03-18 A/S Alfred Benzon Multiple-units drug dose
US4339463A (en) * 1979-08-24 1982-07-13 Shionogi & Co., Ltd. Enterosoluble hard-capsulated medicaments
US4397835A (en) * 1979-08-24 1983-08-09 Shionogi & Co., Ltd. Enterosoluble hard-capsulated medicaments
US4900557A (en) * 1984-08-30 1990-02-13 Troponwerke Gmbh & Co. Kg Pellet formulation
US4863470A (en) * 1985-03-19 1989-09-05 Medical Engineering Corporation Identification marker for a breast prosthesis
US5368027A (en) * 1992-04-23 1994-11-29 Avl Medical Instruments Ag Sensor arrangement for direct or indirect optical determination of physical or chemical properties
US5460798A (en) * 1992-06-22 1995-10-24 Barnett; Patrick A. System for determining the quantity and identity of material ingested by user
US8668737B2 (en) 1997-10-10 2014-03-11 Senorx, Inc. Tissue marking implant
US9039763B2 (en) 1997-10-10 2015-05-26 Senorx, Inc. Tissue marking implant
US20110082547A1 (en) * 1997-10-10 2011-04-07 Senorx, Inc. Tissue marking implant
US8157862B2 (en) 1997-10-10 2012-04-17 Senorx, Inc. Tissue marking implant
US6875182B2 (en) 1998-03-03 2005-04-05 Senorx, Inc. Electrosurgical specimen-collection system
US7229439B2 (en) 1998-03-03 2007-06-12 Senorx, Inc. Apparatus and method for accessing a body site
US6716179B2 (en) 1998-03-03 2004-04-06 Senorx, Inc. Sentinel node location and biopsy
US6638234B2 (en) 1998-03-03 2003-10-28 Senorx, Inc. Sentinel node location and biopsy
US6497706B1 (en) 1998-03-03 2002-12-24 Senorx, Inc. Biopsy device and method of use
US8147487B2 (en) 1998-03-03 2012-04-03 Senorx, Inc. Apparatus and method for accessing a body site
US6758848B2 (en) 1998-03-03 2004-07-06 Senorx, Inc. Apparatus and method for accessing a body site
US7377902B2 (en) 1998-04-08 2008-05-27 Senorx, Inc. Biopsy anchor device with cutter
US7282034B2 (en) 1998-09-01 2007-10-16 Senorx, Inc. Tissue accessing and anchoring device and method
US6679851B2 (en) 1998-09-01 2004-01-20 Senorx, Inc. Tissue accessing and anchoring device and method
US8608713B2 (en) 1998-12-07 2013-12-17 C. R. Bard, Inc. Septum feature for identification of an access port
US8177762B2 (en) 1998-12-07 2012-05-15 C. R. Bard, Inc. Septum including at least one identifiable feature, access ports including same, and related methods
US20100324416A1 (en) * 1999-02-02 2010-12-23 Senorx, Inc. Cavity-filling biopsy site markers
US6347241B2 (en) * 1999-02-02 2002-02-12 Senorx, Inc. Ultrasonic and x-ray detectable biopsy site marker and apparatus for applying it
US20050143656A1 (en) * 1999-02-02 2005-06-30 Senorx, Inc. Cavity-filling biopsy site markers
US6993375B2 (en) 1999-02-02 2006-01-31 Senorx, Inc. Tissue site markers for in vivo imaging
US6996433B2 (en) 1999-02-02 2006-02-07 Senorx, Inc. Imageable biopsy site marker
US20060036165A1 (en) * 1999-02-02 2006-02-16 Senorx, Inc. Tissue site markers for in vivo imaging
US8219182B2 (en) 1999-02-02 2012-07-10 Senorx, Inc. Cavity-filling biopsy site markers
US7047063B2 (en) * 1999-02-02 2006-05-16 Senorx, Inc. Tissue site markers for in vivo imaging
US20060122503A1 (en) * 1999-02-02 2006-06-08 Senorx, Inc. Imageable biopsy site marker
US20060155190A1 (en) * 1999-02-02 2006-07-13 Senorx, Inc. Imageable biopsy site marker
US10172674B2 (en) 1999-02-02 2019-01-08 Senorx, Inc. Intracorporeal marker and marker delivery device
US8224424B2 (en) 1999-02-02 2012-07-17 Senorx, Inc. Tissue site markers for in vivo imaging
US20040193044A1 (en) * 1999-02-02 2004-09-30 Senorx, Inc. Tissue site markers for in vivo imaging
US20090131825A1 (en) * 1999-02-02 2009-05-21 Senorx, Inc. Imageable biopsy site marker
US9861294B2 (en) 1999-02-02 2018-01-09 Senorx, Inc. Marker delivery device with releasable plug
US20110184280A1 (en) * 1999-02-02 2011-07-28 Jones Michael L Intracorporeal marker and marker delivery device
US20040116806A1 (en) * 1999-02-02 2004-06-17 Senorx, Inc. Biopsy site marker and process and apparatus for applying it
US9649093B2 (en) 1999-02-02 2017-05-16 Senorx, Inc. Cavity-filling biopsy site markers
US8361082B2 (en) 1999-02-02 2013-01-29 Senorx, Inc. Marker delivery device with releasable plug
US6662041B2 (en) * 1999-02-02 2003-12-09 Senorx, Inc. Imageable biopsy site marker
US9237937B2 (en) 1999-02-02 2016-01-19 Senorx, Inc. Cavity-filling biopsy site markers
US7565191B2 (en) 1999-02-02 2009-07-21 Senorx, Inc. Tissue site markers for in vivo imaging
US9149341B2 (en) 1999-02-02 2015-10-06 Senorx, Inc Deployment of polysaccharide markers for treating a site within a patient
US8498693B2 (en) 1999-02-02 2013-07-30 Senorx, Inc. Intracorporeal marker and marker delivery device
US9044162B2 (en) 1999-02-02 2015-06-02 Senorx, Inc. Marker delivery device with releasable plug
US20100010342A1 (en) * 1999-02-02 2010-01-14 Senorx, Inc. Tissue site markers for in vivo imaging
US8626270B2 (en) 1999-02-02 2014-01-07 Senorx, Inc. Cavity-filling biopsy site markers
US20040101479A1 (en) * 1999-02-02 2004-05-27 Senorx, Inc. Biopsy site marker and process and apparatus for applying it
US8965486B2 (en) 1999-02-02 2015-02-24 Senorx, Inc. Cavity filling biopsy site markers
US20100198059A1 (en) * 1999-02-02 2010-08-05 Senorx, Inc. Remotely activated marker
US6725083B1 (en) 1999-02-02 2004-04-20 Senorx, Inc. Tissue site markers for in VIVO imaging
US7792569B2 (en) 1999-02-02 2010-09-07 Senorx, Inc. Cavity-filling biopsy site markers
US20110166448A1 (en) * 1999-02-02 2011-07-07 Jones Michael L Marker delivery device with releasable plug
US20050063908A1 (en) * 1999-02-02 2005-03-24 Senorx, Inc. Tissue site markers for in vivo imaging
US20060084865A1 (en) * 1999-02-02 2006-04-20 Burbank Fred H Imageable biopsy site marker
US8579931B2 (en) 1999-06-17 2013-11-12 Bard Peripheral Vascular, Inc. Apparatus for the percutaneous marking of a lesion
US9579159B2 (en) 1999-06-17 2017-02-28 Bard Peripheral Vascular, Inc. Apparatus for the percutaneous marking of a lesion
US20100298698A1 (en) * 2000-11-20 2010-11-25 Senorx, Inc. Tissue site markers for in vivo imaging
US8718745B2 (en) 2000-11-20 2014-05-06 Senorx, Inc. Tissue site markers for in vivo imaging
US8784433B2 (en) 2002-06-17 2014-07-22 Senorx, Inc. Plugged tip delivery tube for marker placement
US8177792B2 (en) 2002-06-17 2012-05-15 Senorx, Inc. Plugged tip delivery tube for marker placement
US7651505B2 (en) 2002-06-17 2010-01-26 Senorx, Inc. Plugged tip delivery for marker placement
US20030233101A1 (en) * 2002-06-17 2003-12-18 Senorx, Inc. Plugged tip delivery tube for marker placement
US8626269B2 (en) 2003-05-23 2014-01-07 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US20090287078A1 (en) * 2003-05-23 2009-11-19 Senorx, Inc. Marker or filler forming fluid
US8639315B2 (en) 2003-05-23 2014-01-28 Senorx, Inc. Marker or filler forming fluid
US7877133B2 (en) 2003-05-23 2011-01-25 Senorx, Inc. Marker or filler forming fluid
US8447386B2 (en) 2003-05-23 2013-05-21 Senorx, Inc. Marker or filler forming fluid
US7983734B2 (en) 2003-05-23 2011-07-19 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US20040236212A1 (en) * 2003-05-23 2004-11-25 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US9801688B2 (en) 2003-05-23 2017-10-31 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US10045832B2 (en) 2003-05-23 2018-08-14 Senorx, Inc. Marker or filler forming fluid
US20040236211A1 (en) * 2003-05-23 2004-11-25 Senorx, Inc. Marker or filler forming fluid
US20040236213A1 (en) * 2003-05-23 2004-11-25 Senorx, Inc. Marker delivery device with releasable plug
US8880154B2 (en) 2003-05-23 2014-11-04 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US20050119562A1 (en) * 2003-05-23 2005-06-02 Senorx, Inc. Fibrous marker formed of synthetic polymer strands
US7970454B2 (en) 2003-05-23 2011-06-28 Senorx, Inc. Marker delivery device with releasable plug
US20110092815A1 (en) * 2003-05-23 2011-04-21 Senorx, Inc. Marker or filler forming fluid
US20100298696A1 (en) * 2003-11-17 2010-11-25 Bard Peripheral Vascular, Inc. Self-contained, self-piercing, side-expelling marking apparatus
US9408592B2 (en) 2003-12-23 2016-08-09 Senorx, Inc. Biopsy device with aperture orientation and improved tip
US8343071B2 (en) 2004-12-16 2013-01-01 Senorx, Inc. Biopsy device with aperture orientation and improved tip
US8360990B2 (en) 2004-12-16 2013-01-29 Senorx, Inc. Biopsy device with aperture orientation and improved tip
US10105125B2 (en) 2004-12-16 2018-10-23 Senorx, Inc. Biopsy device with aperture orientation and improved tip
US8382724B2 (en) 2005-03-04 2013-02-26 C. R. Bard, Inc. Systems and methods for radiographically identifying an access port
US10238850B2 (en) 2005-03-04 2019-03-26 Bard Peripheral Vascular, Inc. Systems and methods for radiographically identifying an access port
US9682186B2 (en) 2005-03-04 2017-06-20 C. R. Bard, Inc. Access port identification systems and methods
US10179230B2 (en) 2005-03-04 2019-01-15 Bard Peripheral Vascular, Inc. Systems and methods for radiographically identifying an access port
US20080140025A1 (en) * 2005-03-04 2008-06-12 C. R. Bard, Inc. Access port identification systems and methods
US8382723B2 (en) 2005-03-04 2013-02-26 C. R. Bard, Inc. Access port identification systems and methods
US20110311337A1 (en) * 2005-03-04 2011-12-22 C.R. Bard, Inc. Access port identification systems and methods
US8029482B2 (en) 2005-03-04 2011-10-04 C. R. Bard, Inc. Systems and methods for radiographically identifying an access port
US9603992B2 (en) 2005-03-04 2017-03-28 C. R. Bard, Inc. Access port identification systems and methods
US9603993B2 (en) 2005-03-04 2017-03-28 C. R. Bard, Inc. Access port identification systems and methods
US8202259B2 (en) 2005-03-04 2012-06-19 C. R. Bard, Inc. Systems and methods for identifying an access port
US9474888B2 (en) 2005-03-04 2016-10-25 C. R. Bard, Inc. Implantable access port including a sandwiched radiopaque insert
US8998860B2 (en) 2005-03-04 2015-04-07 C. R. Bard, Inc. Systems and methods for identifying an access port
US8939947B2 (en) 2005-03-04 2015-01-27 C. R. Bard, Inc. Systems and methods for radiographically identifying an access port
US7959615B2 (en) 2005-03-04 2011-06-14 C. R. Bard, Inc. Access port identification systems and methods
US7785302B2 (en) 2005-03-04 2010-08-31 C. R. Bard, Inc. Access port identification systems and methods
US7947022B2 (en) 2005-03-04 2011-05-24 C. R. Bard, Inc. Access port identification systems and methods
US20100268165A1 (en) * 2005-03-04 2010-10-21 C. R. Bard, Inc. Systems and methods for radiographically identifying an access port
US8603052B2 (en) 2005-03-04 2013-12-10 C. R. Bard, Inc. Access port identification systems and methods
US8585663B2 (en) 2005-03-04 2013-11-19 C. R. Bard, Inc. Access port identification systems and methods
US20060241411A1 (en) * 2005-04-20 2006-10-26 Inrad, Inc. Marking device with retracable cannula
US10016585B2 (en) 2005-04-27 2018-07-10 Bard Peripheral Vascular, Inc. Assemblies for identifying a power injectable access port
US8025639B2 (en) 2005-04-27 2011-09-27 C. R. Bard, Inc. Methods of power injecting a fluid through an access port
US8641676B2 (en) 2005-04-27 2014-02-04 C. R. Bard, Inc. Infusion apparatuses and methods of use
US8641688B2 (en) 2005-04-27 2014-02-04 C. R. Bard, Inc. Assemblies for identifying a power injectable access port
US8545460B2 (en) 2005-04-27 2013-10-01 C. R. Bard, Inc. Infusion apparatuses and related methods
US10183157B2 (en) 2005-04-27 2019-01-22 Bard Peripheral Vascular, Inc. Assemblies for identifying a power injectable access port
US9421352B2 (en) 2005-04-27 2016-08-23 C. R. Bard, Inc. Infusion apparatuses and methods of use
US8475417B2 (en) 2005-04-27 2013-07-02 C. R. Bard, Inc. Assemblies for identifying a power injectable access port
US10052470B2 (en) 2005-04-27 2018-08-21 Bard Peripheral Vascular, Inc. Assemblies for identifying a power injectable access port
US9937337B2 (en) 2005-04-27 2018-04-10 C. R. Bard, Inc. Assemblies for identifying a power injectable access port
US8805478B2 (en) 2005-04-27 2014-08-12 C. R. Bard, Inc. Methods of performing a power injection procedure including identifying features of a subcutaneously implanted access port for delivery of contrast media
US9095325B2 (en) 2005-05-23 2015-08-04 Senorx, Inc. Tissue cutting member for a biopsy device
US8641640B2 (en) 2005-05-23 2014-02-04 Senorx, Inc. Tissue cutting member for a biopsy device
US9750487B2 (en) 2005-05-23 2017-09-05 Senorx, Inc. Tissue cutting member for a biopsy device
US8317725B2 (en) 2005-08-05 2012-11-27 Senorx, Inc. Biopsy device with fluid delivery to tissue specimens
US8915864B2 (en) 2005-08-05 2014-12-23 Senorx, Inc. Biopsy device with fluid delivery to tissue specimens
US10064609B2 (en) 2005-08-05 2018-09-04 Senorx, Inc. Method of collecting one or more tissue specimens
US7572236B2 (en) 2005-08-05 2009-08-11 Senorx, Inc. Biopsy device with fluid delivery to tissue specimens
US7981051B2 (en) 2005-08-05 2011-07-19 Senorx, Inc. Biopsy device with fluid delivery to tissue specimens
US8486028B2 (en) 2005-10-07 2013-07-16 Bard Peripheral Vascular, Inc. Tissue marking apparatus having drug-eluting tissue marker
US20080058640A1 (en) * 2006-08-04 2008-03-06 Senoxrx, Inc. Marker formed of starch or other suitable polysaccharide
US20080039819A1 (en) * 2006-08-04 2008-02-14 Senorx, Inc. Marker formed of starch or other suitable polysaccharide
US20110184449A1 (en) * 2006-08-04 2011-07-28 Senorx, Inc. Marker delivery device with obturator
US20090171198A1 (en) * 2006-08-04 2009-07-02 Jones Michael L Powdered marker
US8437834B2 (en) 2006-10-23 2013-05-07 C. R. Bard, Inc. Breast marker
US9642986B2 (en) 2006-11-08 2017-05-09 C. R. Bard, Inc. Resource information key for an insertable medical device
US9265912B2 (en) 2006-11-08 2016-02-23 C. R. Bard, Inc. Indicia informative of characteristics of insertable medical devices
US20080108949A1 (en) * 2006-11-08 2008-05-08 C. R. Bard, Inc. Resource information key for an insertable medical device
US10092725B2 (en) 2006-11-08 2018-10-09 C. R. Bard, Inc. Resource information key for an insertable medical device
US9901415B2 (en) 2006-12-12 2018-02-27 C. R. Bard, Inc. Multiple imaging mode tissue marker
US20100030072A1 (en) * 2006-12-12 2010-02-04 Casanova R Michael Multiple Imaging Mode Tissue Marker
US9579077B2 (en) 2006-12-12 2017-02-28 C.R. Bard, Inc. Multiple imaging mode tissue marker
US9042965B2 (en) 2006-12-18 2015-05-26 C. R. Bard, Inc. Biopsy marker with in situ-generated imaging properties
US20100010341A1 (en) * 2006-12-18 2010-01-14 Talpade Dnyanesh A Biopsy Marker with In Situ-Generated Imaging Properties
US8401622B2 (en) 2006-12-18 2013-03-19 C. R. Bard, Inc. Biopsy marker with in situ-generated imaging properties
US9533133B2 (en) 2007-06-20 2017-01-03 Medical Components, Inc. Venous access port with molded and/or radiopaque indicia
US8852160B2 (en) 2007-06-20 2014-10-07 Medical Components, Inc. Venous access port with molded and/or radiopaque indicia
US8257325B2 (en) 2007-06-20 2012-09-04 Medical Components, Inc. Venous access port with molded and/or radiopaque indicia
US9610432B2 (en) 2007-07-19 2017-04-04 Innovative Medical Devices, Llc Venous access port assembly with X-ray discernable indicia
US9517329B2 (en) 2007-07-19 2016-12-13 Medical Components, Inc. Venous access port assembly with X-ray discernable indicia
US8021324B2 (en) 2007-07-19 2011-09-20 Medical Components, Inc. Venous access port assembly with X-ray discernable indicia
US20090156928A1 (en) * 2007-11-07 2009-06-18 C. R. Bard, Inc. Radiopaque and septum-based indicators for a multi-lumen implantable port
US9579496B2 (en) 2007-11-07 2017-02-28 C. R. Bard, Inc. Radiopaque and septum-based indicators for a multi-lumen implantable port
US10086186B2 (en) 2007-11-07 2018-10-02 C. R. Bard, Inc. Radiopaque and septum-based indicators for a multi-lumen implantable port
US8311610B2 (en) 2008-01-31 2012-11-13 C. R. Bard, Inc. Biopsy tissue marker
US20100331668A1 (en) * 2008-01-31 2010-12-30 Ranpura Himanshu M Biopsy Tissue Marker
US9327061B2 (en) 2008-09-23 2016-05-03 Senorx, Inc. Porous bioabsorbable implant
US20100082102A1 (en) * 2008-09-23 2010-04-01 Senorx, Inc. Porous bioabsorbable implant
US10052471B2 (en) 2008-11-13 2018-08-21 C. R. Bard, Inc. Implantable medical devices including septum-based indicators
US8932271B2 (en) 2008-11-13 2015-01-13 C. R. Bard, Inc. Implantable medical devices including septum-based indicators
US8670818B2 (en) 2008-12-30 2014-03-11 C. R. Bard, Inc. Marker delivery device for tissue marker placement
US20110028836A1 (en) * 2008-12-30 2011-02-03 Himanshu Ranpura Marker delivery device for tissue marker placement
US20110009828A1 (en) * 2009-07-07 2011-01-13 C.R.Bard, Inc. Extensible internal bolster for a medical device
US8715244B2 (en) 2009-07-07 2014-05-06 C. R. Bard, Inc. Extensible internal bolster for a medical device
US9950150B2 (en) 2009-10-16 2018-04-24 Smiths Medical Asd, Inc. Portal with septum embedded indicia
US9717895B2 (en) 2009-11-17 2017-08-01 C. R. Bard, Inc. Overmolded access port including anchoring and identification features
US20110118677A1 (en) * 2009-11-17 2011-05-19 C. R. Bard, Inc. Overmolded access port including anchoring and identification features
US9079004B2 (en) 2009-11-17 2015-07-14 C. R. Bard, Inc. Overmolded access port including anchoring and identification features
US9248268B2 (en) 2009-11-17 2016-02-02 C. R. Bard, Inc. Overmolded access port including anchoring and identification features
US10155101B2 (en) 2009-11-17 2018-12-18 Bard Peripheral Vascular, Inc. Overmolded access port including anchoring and identification features
USD682416S1 (en) 2010-12-30 2013-05-14 C. R. Bard, Inc. Implantable access port
USD676955S1 (en) 2010-12-30 2013-02-26 C. R. Bard, Inc. Implantable access port
US10145856B2 (en) * 2017-03-22 2018-12-04 Hall Labs, Llc Drug tracking system including food dyes detectable in bodily waste
US9927448B1 (en) * 2017-03-22 2018-03-27 David R. Hall Method of measuring food dyes in bodily waste to identify and quantify drug consumption

Similar Documents

Publication Publication Date Title
Fordtran et al. Intestinal absorption of D-xylose in man
Matthew et al. Gastric aspiration and lavage in acute poisoning.
Bannister et al. Isotope encephalography in the diagnosis of dementia due to communicating hydrocephalus
Kikendall Pill esophagitis
Levy et al. Effect of viscosity on drug absorption
Halsted et al. Absorption of radioactive vitamin B12 in the syndrome of megaloblastic anemia associated with intestinal stricture or anastomosis
Kuehle et al. Hydro-MRI of the small bowel: effect of contrast volume, timing of contrast administration, and data acquisition on bowel distention
PAPPENFORT et al. Moniliasis in patients treated with aureomycin: Clinical and laboratory evidence that aureomycin stimulates the growth of Candida albicans
Lou et al. Focal cerebral hypoperfusion in children with dysphasia and/or attention deficit disorder
Beaver et al. Analgesic studies of codeine and oxycodone in patients with cancer. I. Comparisons of oral with intramuscular codeine and of oral with intramuscular oxycodone.
Madsen Effects of gender, age, and body mass index on gastrointestinal transit times
Holdstock et al. Propulsion (mass movements) in the human colon and its relationship to meals and somatic activity
MERRITT et al. A new series of anticonvulsant drugs tested by experiments on animals
Chiarioni et al. Biofeedback therapy for dyssynergic defecation
Wilding et al. The role of γ-scintigraphy in oral drug delivery
Simpson Simple tests for the detection of urinary PAS
Davis et al. Effect of haloperidol on (+)‐amphetamine self‐administration
Hardy et al. Evaluation of an enteric‐coated delayed‐release 5‐aminosalicylic acid tablet in patients with inflammatory bowel disease
US3852413A (en) Labelled sulfated amylopectins and method of determining abnormal gastrointestinal mucosa
Hirtz The gastrointestinal absorption of drugs in man: a review of current concepts and methods of investigation.
Thomford et al. Lymphoid polyps of the ileum associated with Gardner's syndrome
Schulman et al. Sonographic diagnosis of biliary ascariasis
Kornetsky The use of a simple test of attention as a measure of drug effects in schizophrenic patients
Nevinny et al. Metabolic studies of the effects of methotrexate
EP0303045A1 (en) Pharmaceutical compositions containing magnetic materials